Lexeo Therapeutics Gains Momentum with Positive FDA Discussions

Lexeo Therapeutics shares are trading higher after the company announced progress in FDA discussions for the accelerated approval pathway and revealed positive interim clinical data for LX2006 in Friedreich Ataxia cardiomyopathy.